Want to see VNDA full AI Analyst Report?
VNDA Stock Chart & Stats
$7.27
-$0.20(-4.12%)
At close: 4:00 PM EST
$7.27
-$0.20(-4.12%)
Day’s Range― - ―
52-Week Range$4.14 - $9.94
Previous CloseN/A
Volume240.10K
Average Volume (3M)1.06M
Market Cap
$373.44M
Enterprise Value$317.45M
Total Cash (Recent Filing)$202.31M
Total Debt (Recent Filing)$13.07M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 05, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.05
Shares Outstanding60,135,563
10 Day Avg. Volume1,015,068
30 Day Avg. Volume1,059,560
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.59
Price to Sales (P/S)2.41
P/FCF Ratio-4.71
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.46
Enterprise Value/Gross Profit1.58
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$19.50Price Target Upside168.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.3
Revenue Forecast (FY)$262.00M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum — FanaptSustained, multi-quarter prescription gains and a near-doubled sales force point to durable commercial traction for Fanapt. Strong TRx/NBRx trends and expanded field coverage create a growing, repeatable revenue base that can support scale economies and offset legacy product erosion.
Regulatory & Pipeline ProgressRegulatory approvals and an accepted BLA materially extend addressable markets and create multi-year exclusivity windows. Dysanti has data exclusivity to 02/20/2031 and patents to 05/31/2044; imsidolimab’s PDUFA advances a late-stage asset toward commercialization and potential durable revenue streams.
Low Leverage Balance SheetMinimal debt reduces refinancing and interest burdens, giving management flexibility to fund launches, trials, or strategic investments. Low leverage supports resilience during extended cash burn periods and preserves options for non-dilutive partnerships or disciplined financing when needed.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates the company is consuming cash to fund operations and launches. Continued burn increases reliance on cash reserves or external financing, tightening runway and raising execution risk for multi-year clinical and commercial investments.
Large Operating & Net LossesMaterial operating and net losses erode equity and returns, reducing reinvestment capacity. Even with strong TTM revenue growth, elevated SG&A and R&D are widening losses, impairing long-term profitability prospects and making sustained positive margins contingent on successful launches and cost control.
Hetlioz Erosion From GenericsLoss of a legacy revenue stream to generics removes predictable cash flow and increases dependence on new product launches. This structural decline compels higher commercial investment to replace sales, raising execution risk and pressuring margins until new assets scale.
Vanda News
VNDA FAQ
What was Vanda Pharmaceuticals’s price range in the past 12 months?
Vanda Pharmaceuticals lowest stock price was $4.14 and its highest was $9.94 in the past 12 months.
What is Vanda Pharmaceuticals’s market cap?
Vanda Pharmaceuticals’s market cap is $373.44M.
When is Vanda Pharmaceuticals’s upcoming earnings report date?
Vanda Pharmaceuticals’s upcoming earnings report date is Aug 05, 2026 which is in 32 days.
How were Vanda Pharmaceuticals’s earnings last quarter?
Vanda Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.688 by -$0.132.
Is Vanda Pharmaceuticals overvalued?
According to Wall Street analysts Vanda Pharmaceuticals’s price is currently Undervalued.
Does Vanda Pharmaceuticals pay dividends?
Vanda Pharmaceuticals does not currently pay dividends.
What is Vanda Pharmaceuticals’s EPS estimate?
Vanda Pharmaceuticals’s EPS estimate is -0.58.
How many shares outstanding does Vanda Pharmaceuticals have?
Vanda Pharmaceuticals has 60,135,563 shares outstanding.
What happened to Vanda Pharmaceuticals’s price movement after its last earnings report?
Vanda Pharmaceuticals reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.688. Following the earnings report the stock price went down -14.113%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals?
Currently, no hedge funds are holding shares in VNDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vanda Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.50 (168.23% Upside)
$19.50 (168.23% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 206.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.99%
12-Months-Change
Fundamentals
Return on Equity
-61.41%
Trailing 12-Months
Asset Growth
-31.40%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
VNDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive commercial and pipeline momentum story: Fanapt demonstrated strong prescription growth and the company launched Nirius via a novel direct‑to‑consumer model while securing FDA approval for Dysanti and advancing imsidolimab toward potential year‑end regulatory action. Management raised 2026 revenue guidance and outlined multiple upcoming Phase 3 readouts that could be value drivers. Offsetting these positives are a materially larger Q1 net loss, increased operating expenses, a significant cash decline and ongoing Hetlioz erosion from generics, plus some development and recruitment risks for certain programs. Overall, commercial and regulatory catalysts appear to outweigh near‑term financial pressures.View all VNDA earnings summariesVNDA Stock 12 Month Forecast
Average Price Target
$19.50
▲(168.23% Upside)
Technical Analysis
Ownership Overview
8.85% Insiders
13.94% Mutual Funds
<0.01% Other Institutional Investors
59.95% Public Companies and
Individual Investors